Otsuka FDA Approval marks a significant milestone with the first anti-APRIL therapy for IgA nephropathy, impacting the rare kidney disease market.
Author: PharmaSignal News Desk
Medicare price negotiation reduces spending by 44% for Wegovy, Trelegy, and 13 other drugs, impacting 2027 prices.
Big Pharma CEO ratings reveal which leaders earn the highest employee approval, showcasing the impact of executive leadership on company culture.
Kelun Merck ADC shows promise in lung cancer treatment, succeeding in a late-stage trial with potential first-line approval.
Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous setbacks.
Novo Nordisk GLP-1 drug fails to meet primary endpoints in Alzheimer’s trials, impacting neurodegeneration treatment hopes.
Takeda rare disease drug is under FDA investigation following a patient death and reports of neutralizing antibodies.
Novartis job cuts affect hundreds in Swiss manufacturing, while Novo’s diabetes drug advances to Phase 3 trials.
Otsuka FDA approval marks a first for anti-APRIL therapy targeting IgA nephropathy, potentially impacting the rare kidney disease market.
Medicare price negotiation reduces costs by 44% for Wegovy, Trelegy, and 13 other drugs by 2027.